Atara Biotherapeutics (ATRA) Current Assets (2013 - 2026)
Atara Biotherapeutics' (ATRA) quarterly Current Assets came in at $12.2 million in Q1 2026, down 55.22% YoY from $27.2 million in Q1 2025, and little changed on a QoQ basis from $12.2 million in Q4 2025.
Atara Biotherapeutics (ATRA) Current Assets (2013 - 2026) Analysis & Trends
Atara Biotherapeutics (ATRA) has 14 years of Current Assets data on file, last reported at $12.2 million in Q1 2026.
- Quarterly Current Assets fell 55.22% year-over-year to $12.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.2 million (down 55.22% YoY) and the FY2025 annual result came in at $12.2 million, down 81.18% from the prior year.
- Current Assets steadied at $12.2 million in Q1 2026, from $12.2 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $347.0 million in Q2 2022 to a low of $12.2 million in Q1 2026.
- A 5-year average of $133.9 million and a median of $101.9 million in 2023 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2022 — Current Assets slipped 11.56% — and 2025, when it slumped 81.18%.
- Tracing ATRA's Current Assets over 5 years: stood at $295.1 million in 2022, then sank by 65.48% to $101.9 million in 2023, then slumped by 36.3% to $64.9 million in 2024, then tumbled by 81.18% to $12.2 million in 2025, then slipped by 0.32% to $12.2 million in 2026.
- The last three Current Assets figures came in at $12.2 million (Q1 2026), $12.2 million (Q4 2025), and $18.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.65 Bn | 131.79 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 86.08 Bn | 78.09 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 65.16 Bn | 59.98 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 63.25 Bn | 58.11 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 42.22 Bn | 37.12 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.26 Bn | 27.95 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.96 Bn | 10.57 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.19 Bn | 26.35 Bn | - | 1.76 Bn |
| 10 | Atara Biotherapeutics | 146.12 Mn | 129.57 Mn | 439,000.00 | 13.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.53 Mn |
| Mar 31, 2026 | 12.17 Mn |
| Dec 31, 2025 | 12.21 Mn |
| Sep 30, 2025 | 18.43 Mn |
| Jun 30, 2025 | 24.77 Mn |
| Mar 31, 2025 | 27.18 Mn |
| Dec 31, 2024 | 64.89 Mn |
| Sep 30, 2024 | 91.86 Mn |
| Jun 30, 2024 | 62.41 Mn |
| Mar 31, 2024 | 106.43 Mn |
| Dec 31, 2023 | 101.87 Mn |
| Sep 30, 2023 | 118.70 Mn |
| Jun 30, 2023 | 172.32 Mn |
| Mar 31, 2023 | 224.18 Mn |
| Dec 31, 2022 | 295.08 Mn |
| Sep 30, 2022 | 283.05 Mn |
| Jun 30, 2022 | 346.98 Mn |
| Mar 31, 2022 | 314.39 Mn |
| Dec 31, 2021 | 384.62 Mn |
| Sep 30, 2021 | 369.50 Mn |